| Title |
Treatment Options in Newly Diagnosed Glioblastoma
|
|---|---|
| Published in |
Current Treatment Options in Neurology, April 2013
|
| DOI | 10.1007/s11940-013-0226-9 |
| Pubmed ID | |
| Authors |
Eudocia Q. Lee, Lakshmi Nayak, Patrick Y. Wen, David A. Reardon |
| Abstract |
Regardless of MGMT status, standard of care for a patient with newly diagnosed glioblastoma (GBM), age ≤70 years, and adequate functional status is radiation and concurrent temozolomide followed by adjuvant temozolomide. For elderly patients, recent studies have suggested that standard radiation, hypofractionated radiation, or single agent temozolomide are acceptable treatment options. Randomized phase III studies of bevacizumab in combination with radiation and temozolomide for newly diagnosed GBM have completed accrual. Preliminary results reveal a clear progression-free survival benefit. Overall survival appears unchanged although follow-up has not fully matured and cross-over to bevacizumab upon progression among control patients may limit definitive conclusions. Although bevacizumab in the upfront setting may be considered for a subset of patients, it should not be used routinely in newly diagnosed patients until final results are available. Clinical trials evaluating promising therapeutics given in combination with standard temozolomide chemoradiation are critically needed. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Turkey | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 4% |
| India | 1 | 2% |
| Netherlands | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 47 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 15% |
| Researcher | 8 | 15% |
| Student > Ph. D. Student | 8 | 15% |
| Student > Postgraduate | 4 | 8% |
| Student > Doctoral Student | 4 | 8% |
| Other | 9 | 17% |
| Unknown | 11 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 35% |
| Agricultural and Biological Sciences | 8 | 15% |
| Nursing and Health Professions | 4 | 8% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Unspecified | 3 | 6% |
| Other | 5 | 10% |
| Unknown | 11 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 May 2013.
All research outputs
#17,683,485
of 22,703,044 outputs
Outputs from Current Treatment Options in Neurology
#346
of 468 outputs
Outputs of similar age
#144,849
of 199,687 outputs
Outputs of similar age from Current Treatment Options in Neurology
#8
of 13 outputs
Altmetric has tracked 22,703,044 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 468 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,687 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.